Hangzhou Haoli Technology
Microfluidic chip company specializing in digital production of life science microsphere materials.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
Related Content
Established in 2022 and based in Hangzhou, China, Hangzhou Haoli Technology is a seed-stage enterprise focused on the development of microfluidic chips for industrial life science applications. The company specializes in creating 'Lab-On-a-Chip' (LOC) technology, a platform designed for the high-precision manufacturing of microspheres, the mass production of advanced drug delivery systems, and the synthesis of various biomedical particles.
The firm's core business involves providing specialized microfluidic solutions to clients in the biomedical and pharmaceutical industries. Its revenue model is centered on the sale of these high-tech microfluidic chips and potentially licensing its proprietary LOC technology. By enabling the mass production of complex particles, the company addresses critical needs in drug formulation and biomedical research.
In March 2023, Hangzhou Haoli Technology secured an undisclosed amount in a seed funding round, with Linear Venture being the lead investor. This initial capital injection is aimed at advancing its research and development efforts and scaling its manufacturing capabilities to meet growing market demand for precise drug delivery and biomedical components. The company operates in a competitive field alongside firms developing technologies for life science research and molecular diagnostics.
Keywords: microfluidics, Lab-On-a-Chip, life sciences, drug delivery systems, biomedical particles, microsphere manufacturing, particle synthesis, Hangzhou, Linear Venture, seed funding, biotechnology, pharmaceutical technology, LOC technology, precision manufacturing